-
·
Published:FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
PRECISIS, a German neurotechnology company developing minimally invasive brain-stimulation therapies, has received FDA authorization to begin a pivotal clinical trial of its EASEE® system for drug-resistant focal epilepsy – a step that moves the company closer to entering the U.S. market. The pivotal study, following the device’s Breakthrough Designation, will evaluate safety and efficacy in…
-
·
Published:European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Heidelberg/Berlin, July 24 2025. Precisis, a Heidelberg-based MedTech innovator developing personalized neurostimulation technology for neurological disorders, announced today the closing of a €20 million venture loan from the European Investment Bank (EIB). This funding complements the company’s recently started efforts to raise an additional €37 million in equity financing as part of its Series B…
-
·
Published:150 Patients – 150 Times New Hope
We at PRECISIS are proud to announce a major milestone: 150 patients implanted with EASEE® across Europe. This achievement marks a significant step forward in our mission to improve the lives of people living with drug-resistant focal epilepsy. EASEE®, which received its CE mark in September 2022, is now actively implanted by leading epileptologists and neurosurgeons in…
